Please login to the form below

Not currently logged in
Email:
Password:

RRMS

This page shows the latest RRMS news and features for those working in and with pharma, biotech and healthcare.

Teva drops laquinimod for most common form of MS after failed trial

Teva drops laquinimod for most common form of MS after failed trial

balance Teva said it has "no current plans to further pursue laquinimod in RRMS".

Latest news

  • Novartis drug works in secondary progressive MS Novartis drug works in secondary progressive MS

    Roche has reported encouraging data with Ocrevus, a humanised monoclonal antibody designed to selectively target CD20-positive B cells (ocrelizumab) in RRMS, and SPMS and also primary progressive MS, an

  • Novartis wins partial reprieve for Gilenya in Germany Novartis wins partial reprieve for Gilenya in Germany

    On the basis of the new analyses, there was an indication, and no longer a hint of an added benefit in patients with rapidly evolving severe RRMS. ... The new analyses of Novartis' TRANSFORMS study also showed that Gilenya has advantages for patients

  • Biogen Idec enlists son of NFL star for MS campaign Biogen Idec enlists son of NFL star for MS campaign

    However, after a promising college career Tyler Campbell was diagnosed with relapsing-remitting MS (RRMS) and had to give up his sports dream. ... Three winning entries will be picked to win a prize of tickets to a sporting event with Campbell or Chris

  • Novartis’ Gilenya fails in difficult-to-treat form of MS Novartis’ Gilenya fails in difficult-to-treat form of MS

    PPMS is thought to affect 10% of MS patients and differs from the more common relapsing remitting form of MS (RRMS) that sees patients experience acute attacks or exacerbations and periods ... Gilenya was approved in RRMS in 2010, revolutionising

  • Sanofi persuades FDA to back its MS drug Lemtrada Sanofi persuades FDA to back its MS drug Lemtrada

    The FDA initially rejected Genzyme's marketing application for the drug's use in RRMS at the beginning of the year claiming the company "had not submitted evidence from adequate and

More from news
Approximately 8 fully matching, plus 29 partially matching documents found.

Latest from PMHub

  • It's time to change the conversation

    Take Multiple Sclerosis (MS) for example. MS has four different disease manifestations: Relapsing Remitting (RRMS), Secondary Progressive (SPMS), Primary Progressive (PPMS) and Progressive Relapsing (PRMS). ... Today however, given the research and the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics